Table 5.
Protective immunity generated by both HLA-A2.1 restricted epitopes after combined peptide and DNA vaccination at week 9 following CRPV-HPV16E7/82–90 hybrid DNA challenge
| Vaccine | Site free of papillomas |
Sites with papillomas |
Protection rate |
|---|---|---|---|
| TT helper fused CRPVE1/303–311 (N=5) |
20 | 0 | 20/20 (100%)a |
| PADRE fused CRPVE1/303–311 (N=5) |
16 | 4 | 16/20 (80%)b |
| TT helper fused HPV16E7/82–90 (N=5) |
15 | 5 | 15/20 (75%) |
| PADRE fused HPV16E7/82–90 (N=4) |
9 | 7 | 9/16 (56.25%) |
a
P<0.05 and
b
P>0.05 vs. corresponding control group respectively, Fisher’s exact test